search
Back to results

Electronic Cigarettes in Smokers With Mental Illness (APUS e-Cigs)

Primary Purpose

Schizophrenia, Schizophreniform Disorder, Bipolar Disorder

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
disposable electronic cigarettes
Sponsored by
King's College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Schizophrenia focused on measuring electronic cigarettes, smoking, schizophrenia, serious mental illness

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • smokers (≥ 5 cigarettes/day for > 1 yr and breath CO > 5 ppm)
  • ages 18-65 years
  • ICD-10 diagnosis of schizophreniform, schizophrenia, schizoaffective or bipolar disorder

Exclusion Criteria:

  • used e-cigs on > 2 occasions in the past 30 days;
  • intend to quit smoking within the next 30 days;
  • currently use medications that may reduce smoking (bupropion, varenicline, NRT, naltrexone, buprenorphine, acamprosate, baclofen, clonidine, nortriptyline, anti-seizure medications, disulfiram);
  • have unstable psychiatric conditions (hospitalization or change in dose of chronic medication in the past 30 days);
  • People with a serious medical condition including uncontrolled high blood pressure, something wrong with their heart or blood vessels that occurred or got worse in the past 3 months (including fast or irregular heart rhythm, angina, chest pain, had a heart attack or stroke).
  • People who have ever had a serious stomach ulcer, and/or phaeochromocytoma (tumor of the adrenal gland).
  • People who in the last 3 months have had severe heartburn; or a stroke, or unstable kidney disease, unstable liver disease, uncontrolled over-active thyroid gland
  • met DSM-IV criteria for drug dependence
  • have medical contraindications to nicotine, since nicotine intake may increase in this study;
  • have past-month suicidal ideation or past-year suicide attempt.
  • are pregnant, as determined through a pregnancy test

Sites / Locations

  • South London and Maudsley Foundation Trust (SLaM)

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Electronic cigarettes

Arm Description

Free disposable electronic cigarettes will be provided during 6 weeks to smokers with serious mental illness.

Outcomes

Primary Outcome Measures

Electronic cigarette use
Time Line Follow Back (TLFB) questionnaire
electronic cigarette acceptability
electronic cigarette evaluation scale (it measures product liking, satisfaction, sensory and physical effects)
Respiratory symptoms
An abbreviated and adapted version of the American Thoracic Society Questionnaire (ATS) will be used to assess respiratory symptoms.
Cotinine
Cotinine levels in urine
Nitrosamines
NNAL and 3-HPMA levels in urine
Side effects of antipsychotics
The Udvalg for Kliniske Undersøgelser (UKU) scale
Withdrawal symptoms
Mood and Physical Symptoms Scale, MPSS
Respiratory symptoms
Peak Expiratory Flow Rate (PEFR) to monitor airway obstruction, assess its severity and variation.

Secondary Outcome Measures

Predictors of e-Cigs use
Motivation To Stop Scale -MTSS-
Predictors of e-Cigs use
Smoking Consequences Questionnaire
Psychiatric symptoms
Positive and Negative Syndrome Scale
Psychiatric symptoms
Calgary Depression Scale for Schizophrenia
Physical symptoms
Blood pressure and heart rate

Full Information

First Posted
August 6, 2014
Last Updated
May 15, 2017
Sponsor
King's College London
search

1. Study Identification

Unique Protocol Identification Number
NCT02212041
Brief Title
Electronic Cigarettes in Smokers With Mental Illness
Acronym
APUS e-Cigs
Official Title
Acceptability, Patterns of Use and Safety of Electronic Cigarette in People With Mental Illness: a Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
September 24, 2014 (Actual)
Primary Completion Date
May 2, 2017 (Actual)
Study Completion Date
May 2, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King's College London

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
People with mental illness are more likely to smoke and are more severely addicted to nicotine than the general population. As a result, the number of deaths related to tobacco is higher. Smoking is highly addictive because it delivers nicotine very quickly. Research studies show that people who use nicotine replacement therapies (such us patches, gums, etc) are more likely to quit smoking than those who try to quit without using these nicotine products. Recently a new electronic nicotine delivery system (ENDS), also known as electronic cigarette (e-cigarette) is rapidly gaining popularity. Electronic cigarettes are devices that mimic traditional cigarettes and deliver nicotine but do not carry the dangerous chemicals contained in tobacco cigarettes. Given the increasing popularity of e-cigs, there is an urgent need to improve our understanding of both the potential benefits and risks of e-cigs use in people with serious mental illness. In this pilot we propose inviting 50 people with schizophrenia (or schizophrenia-related disorder) who are not intending to quit smoking in the near future to take part in a study in which we will provide 6-weeks of free e-cigs, followed by a 4-week period in which they will not receive free e-cigs and we monitor which products participants choose, and a final 24-week follow-up visit. During the 24-week study period we will assess the use of e-cigs and tobacco cigarettes, the exposure to nicotine and tobacco toxicants, nicotine withdrawal symptoms, the changes in respiratory symptoms and psychiatric symptoms as well as the e-cigs perceived benefits and risks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia, Schizophreniform Disorder, Bipolar Disorder
Keywords
electronic cigarettes, smoking, schizophrenia, serious mental illness

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Electronic cigarettes
Arm Type
Experimental
Arm Description
Free disposable electronic cigarettes will be provided during 6 weeks to smokers with serious mental illness.
Intervention Type
Other
Intervention Name(s)
disposable electronic cigarettes
Other Intervention Name(s)
NJOY
Intervention Description
Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette. During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained.
Primary Outcome Measure Information:
Title
Electronic cigarette use
Description
Time Line Follow Back (TLFB) questionnaire
Time Frame
weekly measurements from baseline to 10 weeks and a final assessment at 24 weeks
Title
electronic cigarette acceptability
Description
electronic cigarette evaluation scale (it measures product liking, satisfaction, sensory and physical effects)
Time Frame
Baseline, week 2, week6, week 10 and week 24
Title
Respiratory symptoms
Description
An abbreviated and adapted version of the American Thoracic Society Questionnaire (ATS) will be used to assess respiratory symptoms.
Time Frame
weekly measures from baseline to 10 weeks and at 24 weeks
Title
Cotinine
Description
Cotinine levels in urine
Time Frame
Baseline, week 2, 6, 10 and 24
Title
Nitrosamines
Description
NNAL and 3-HPMA levels in urine
Time Frame
Baseline and at 6 week
Title
Side effects of antipsychotics
Description
The Udvalg for Kliniske Undersøgelser (UKU) scale
Time Frame
weekly the first 10 weeks and at 24 weeks
Title
Withdrawal symptoms
Description
Mood and Physical Symptoms Scale, MPSS
Time Frame
weekly the first 10 weeks and at 24 weeks
Title
Respiratory symptoms
Description
Peak Expiratory Flow Rate (PEFR) to monitor airway obstruction, assess its severity and variation.
Time Frame
weekly the first 10 weeks and at 24 weeks
Secondary Outcome Measure Information:
Title
Predictors of e-Cigs use
Description
Motivation To Stop Scale -MTSS-
Time Frame
Baseline, week 2, 6, 10 and 24.
Title
Predictors of e-Cigs use
Description
Smoking Consequences Questionnaire
Time Frame
Baseline, week 2, 6, 10 and 24
Title
Psychiatric symptoms
Description
Positive and Negative Syndrome Scale
Time Frame
weekly during the first 10 weeks and at 24 weeks
Title
Psychiatric symptoms
Description
Calgary Depression Scale for Schizophrenia
Time Frame
weekly the first 10 weeks and at 24 weeks
Title
Physical symptoms
Description
Blood pressure and heart rate
Time Frame
weekly the first 10 weeks and at 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: smokers (≥ 5 cigarettes/day for > 1 yr and breath CO > 5 ppm) ages 18-65 years ICD-10 diagnosis of schizophreniform, schizophrenia, schizoaffective or bipolar disorder Exclusion Criteria: used e-cigs on > 2 occasions in the past 30 days; intend to quit smoking within the next 30 days; currently use medications that may reduce smoking (bupropion, varenicline, NRT, naltrexone, buprenorphine, acamprosate, baclofen, clonidine, nortriptyline, anti-seizure medications, disulfiram); have unstable psychiatric conditions (hospitalization or change in dose of chronic medication in the past 30 days); People with a serious medical condition including uncontrolled high blood pressure, something wrong with their heart or blood vessels that occurred or got worse in the past 3 months (including fast or irregular heart rhythm, angina, chest pain, had a heart attack or stroke). People who have ever had a serious stomach ulcer, and/or phaeochromocytoma (tumor of the adrenal gland). People who in the last 3 months have had severe heartburn; or a stroke, or unstable kidney disease, unstable liver disease, uncontrolled over-active thyroid gland met DSM-IV criteria for drug dependence have medical contraindications to nicotine, since nicotine intake may increase in this study; have past-month suicidal ideation or past-year suicide attempt. are pregnant, as determined through a pregnancy test
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rocio Perez-Iglesias, MD, PhD
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ann McNeill, BSc, PhD, Prof
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lynne Dawkins, BSc, PhD
Organizational Affiliation
University of East London
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
John Moxham, MD, PhD, Prof
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Philip McGuire, MD, PhD, Prof
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
South London and Maudsley Foundation Trust (SLaM)
City
London
ZIP/Postal Code
SE5 8AF
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
29986786
Citation
Hickling LM, Perez-Iglesias R, McNeill A, Dawkins L, Moxham J, Ruffell T, Sendt KV, McGuire P. A pre-post pilot study of electronic cigarettes to reduce smoking in people with severe mental illness. Psychol Med. 2019 Apr;49(6):1033-1040. doi: 10.1017/S0033291718001782. Epub 2018 Jul 10. Erratum In: Psychol Med. 2019 Feb;49(3):528.
Results Reference
derived

Learn more about this trial

Electronic Cigarettes in Smokers With Mental Illness

We'll reach out to this number within 24 hrs